Biosimilars – Page 2

Biosimilar stability comparability failure after cell line or upstream change: CAPA strategy to restore similarity and prevent regulatory delays

Recognizing the symptoms of stability and comparability failures early is essential for effective intervention. Symptoms can manifest as deviations during in-process testing, unexpected results during stability studies, or customer complaints…

Biosimilar aggregate level increase during FDA/EMA scientific advice / meetings: CAPA strategy to restore similarity and prevent regulatory delays

Recognizing symptoms and signals early in the biosimilar development process is crucial for timely intervention. Common indicators of an increase in aggregate levels may include:Click to read the full article.

Biosimilar aggregate level increase after cell line or upstream change: inspection-ready evidence pack for comparability and lifecycle management

The first step in addressing a potential issue related to increased biosimilar aggregate levels is recognizing the symptoms. Common signals include:Click to read the full article.

Biosimilar glycan profile mismatch during analytical similarity assessment: FDA/EMA expectations for root cause, rework, and comparability justification

Identifying the symptoms or signals related to glycan profile mismatches is crucial for timely deviation investigations. These signals may include:Click to read the full article.

Biosimilar glycan profile mismatch during BLA/MAA review: how to build a defensible similarity narrative with data integrity controls

Identifying mismatches in glycan profiles starts with observing specific symptoms that may signal a deviation or out-of-specification (OOS) result. Clinicians and laboratory personnel should remain vigilant for the following indicators:Click…

Biosimilar residual HCP / DNA OOS during comparability protocol execution: decision tree for lab method variability vs true product differences

Identifying the initial signs of a potential issue is crucial in the investigation of OOS results. Symptoms associated with elevated levels of residual HCP or DNA during comparability protocol execution…

Biosimilar residual HCP / DNA OOS during BLA/MAA review: bridging study planning and regulatory communication strategy

Identifying symptoms signaling potential OOS results is crucial in promptly addressing issues related to biosimilar product quality. Symptoms may manifest in several forms:Click to read the full article.

Biosimilar aggregate level increase after manufacturing site change: how to build a defensible similarity narrative with data integrity controls

When aggregate levels in biosimilars increase following a site change, several telltale signs may emerge on the production floor or within lab settings. Symptoms often include:Click to read the full…

Biosimilar aggregate level increase after downstream resin change: CAPA strategy to restore similarity and prevent regulatory delays

During routine quality control (QC) assessments, several signals may indicate a problem with biosimilar aggregate levels. These include:Click to read the full article.

Biosimilar reference standard qualification gap during stability pull comparisons: inspection-ready evidence pack for comparability and lifecycle management

The initial step in addressing a potential qualification gap in biosimilar reference standards is identifying the symptoms and signals that indicate a problem. Signs of issues may include:Click to read…

Biosimilar stability comparability failure after downstream resin change: bridging study planning and regulatory communication strategy

The first step in any investigation is identifying the signals indicating a potential stability comparability failure. This can manifest through:Click to read the full article.

Biosimilar reference standard qualification gap during stability pull comparisons: bridging study planning and regulatory communication strategy

Symptoms indicative of a biosimilar reference standard qualification gap can manifest in various forms within both laboratory and production environments. These can include:Click to read the full article.